Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-12-05
2006-12-05
Smith, Lynette R. F. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023700, C536S023400, C536S023740, C435S069800, C435S069700, C435S069300, C435S069100
Reexamination Certificate
active
07144998
ABSTRACT:
Recombinant polypeptides are prepared using novel nucleic acids with transcription promoter activity. The recombinant cells containing said nucleic acids are described. A novel method for preparing antigens or antigen fragments, in particular bacterial toxins, preferablyClostridumtoxins, for preparing immunogenic and/or vaccine compositions is also described.
REFERENCES:
patent: 5004692 (1991-04-01), Tso et al.
patent: 5177017 (1993-01-01), Lin et al.
patent: 5192669 (1993-03-01), Schoner et al.
patent: 5266474 (1993-11-01), Miller
patent: 5418157 (1995-05-01), Lin et al.
patent: 5496725 (1996-03-01), Yu
patent: 5529908 (1996-06-01), Palva et al.
patent: 5538851 (1996-07-01), Fach et al.
patent: 5814477 (1998-09-01), Williams et al.
patent: 5874220 (1999-02-01), Fach et al.
patent: 5955368 (1999-09-01), Johnson et al.
patent: 6015709 (2000-01-01), Natesan
patent: 6133506 (2000-10-01), Topfer et al.
patent: 6214602 (2001-04-01), Zdanovsky
patent: 6280993 (2001-08-01), Yamato et al.
patent: 6323023 (2001-11-01), Shoseyov et al.
patent: 6403094 (2002-06-01), Titball et al.
patent: 6713617 (2004-03-01), Minoprio et al.
patent: 6939548 (2005-09-01), Wilkins et al.
patent: 2002/0182229 (2002-12-01), Brown et al.
patent: 0 453 216 (1991-10-01), None
patent: WO 95/17521 (1995-06-01), None
patent: WO 97/34001 (1997-09-01), None
Perelle, S et al, Infection and Immunity, Dec. 1993, vol. 61(12), pp. 5147-5146, (abstract only).
Perella, S et al, Infection and Immunity, Dec. 1995, vol. 63(12), p. 4967, (abstract only).
Hunter, SEC et al, Infection and Immunity, Sep. 1993, p. 3958-3965, vol. 61(9), Molecular genetic analysis of beta toxin ofClostridium perfringensreveals sequence homology with alpha-toxin, gamma toxin and leukocidin ofStaphylococcus aureus.
Bullifent, HL et al, FEMS Microbiology Letters, vol. 131, pp. 99-105, 1995.
Gibert, M et al, Gene, vol. 203, pp. 65-73, 1997.
Draper et al, Genbank accesstion No. I78403, (US Pat5,693,535 sequence SEQ ID No. 201).
Levine et al, Genbank accession No. AAT97603, (WO97/37685, publication date Oct. 16, 1997).
Matteucci et al, Genbank accession No. AAQ20161, (WO91/18997) publication date Dec. 12, 1991.
Hunter, SEC et al., Infection and Immunity, vol. 61(9), pp. 3958-3965, Sep. 1993.
Steinporsdottir, V et al, FEMS Microbiology Letters, vol. 130, pp. 273-278, 1995.
Hunter, SEC et al, Infection and Immunity, Sep. 1993, vol. 61(9), pp. 3958-3965.
Hunter et al (1993), Infection and Immunity, vol. 61(9), pp. 3958-3965, Sep.
Graves et al (1986), The journal of biological Chemistry, vol. 261(24), pp. 11409-11415, Aug. 25, 1986.
Brown, Robert Christopher, PH.D. (1997) Open University (United Kingdom) vol. 58/04C of Dissertation Abstracts International, p. 1203, Development of a novel expression system in clostridium perfringens (gene expression, shuttle vector).
Garnier, T et al, Plasmid, vol. 19, pp. 151-160, 1988.
Narberhaus, F et al, Journal of Bacteriology, May 1992, vol. 174(10),pp. 3282-3289.
Saint-Joanis, B et al, Mol. Gen. Genet., 1989, vol. 219, pp. 453-460.
Sauer, Uwe et al, Journal of Bacteriology, vol. 176(21), pp. 6572-6582, Nov. 1994.
Holck, A et al, Gene, 1990, vol. 91(1), pp. 107-111.
Garnier, T et al, Journal of Bacteriology, Sep. 1991, vol. 173(17), pp. 5431-5438.
Kobayashi, T et al, FEMS Microbiology Letters, vol. 133, pp. 65-69, 1995.
Lyristis,M et al, Molecular Microbiology, vol. 12(5), pp. 761-777, Jun. 1994.
Hunter, SEC et al, Infection and Immunity, vol. 60(1), pp. 102-110, Jan. 1992.
Bullifent, Helen L et al, FEMS Microbiology Letters, vol. 131, (1995),p. 99-105, The Construction of a reporter system and use for the investigation ofClostridium perfringensgene expression.
Matsushita, C et al, Microbiology, 1996, vol. 142, pp. 2561-2566.
Melville, Stephen B e tal, Infection and Immunity, vol. 62(12), p. 5550-5558, Dec. 1994.
Pickett, Carol L et al, Infection and Immunity, vol. 64(6), pp. 2070-2078, Jun. 1996.
Song, Keang-Peng, Ph.D., 1995, Evidence supporting an operon model for the expression of toxins A and B by Clostridium difficile (pseudomembranous colitis, promoter), vol. 56(08-b), Texas Tech. University (abstract only).
Brown, Robert Christopher, Ph. D. 1997, Open University, (United Kingdom) Development of a novel expression system inClostridium perfringens(gene expression, shuttle vector), complete dissertation, figures and tables, pp. 1-216.
Brown et al (reference of record). □□.
Hunter et al (reference of record).
Swiss-Prot Accession No. Q46102, created date Nov. 1996, Cytolethal distending toxin C of Campylobacter jejuni.
Hunter et al, “Cloning and Nucleotide Sequencing of theClostridium perfringensEpsilon-Toxin Gene and Its Pression inEscherichia coli”, Infection and Immunity, vol. 60, No. 1, pp. 102-110, Jan. 1992.
Bullifent et al, “The Construction of a Reporter System and Use for the Investigation ofClostridium perfringensGene Expression”, FEMS Microbiology Letters, vol. 131, No. 1, pp. 99-105, Aug. 15, 1995.
Gibert et al. “BETA2 Toxin, A Novel Toxin Produced byClostridium perfringens”, GEN pp. 65-73, Dec. 5, 1997.
Gibert Maryse
Popoff Michel-Robert
Institut Pasteur
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Clostridium perfringens beta-2 toxin signal sequence,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clostridium perfringens beta-2 toxin signal sequence,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridium perfringens beta-2 toxin signal sequence,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693588